_
Alzheimer's cure: World General Media News Headlines
Alzheimer's treatment: World General Media News Headlines
Alzheimer theories: World General Media News Headlines
Alzheimer science professional news: Alzforum News & Views
February 24, 2007
TorreyPines Therapeutics and Eisai Co., Ltd. Extend Alzheimer's Disease
Announced the extension of an exclusive collaboration agreement between TorreyPines and Eisai Co., Ltd. that began in February 2005.
LA JOLLA, CA, USA TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) today announced the extension of an exclusive collaboration agreement between TorreyPines and Eisai Co., Ltd. that began in February 2005. This collaboration, focusing on the discovery of novel, small molecules to treat Alzheimer’s disease, is TorreyPines’ second discovery collaboration with Eisai. In a separate series of agreements, dating back to 2001, Eisai and TorreyPines are collaborating in a genetics program to discover Alzheimer’s disease targets using whole-genome family-based association screening.
The goal of the small molecule program is to discover novel Alzheimer’s disease modifying compounds based on the study of the mechanism of the disease’s pathogenesis. Under the original agreement, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research. TorreyPines and Eisai may enter into development agreements involving the validated compounds.
“We are excited about extending this agreement with Eisai, a leader in Alzheimer’s disease research and treatment,” said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. “We look forward to advancing the small molecule program further with Eisai’s support, as well as to continuing to work with them on our initial research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer’s disease.”
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics is a clinical stage biopharmaceutical company that discovers and develops small molecule drugs to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer’s disease. TorreyPines’ common stock is traded on The NASDAQ Global Stock Market under the symbol "TPTX." For detailed company information, including copies of this and other press releases, please visit TorreyPines’website at www.torreypinestherapeutics.com...
Source: TorreyPines Therapeutics, Inc [FullText]
LA JOLLA, CA, USA TorreyPines Therapeutics, Inc. (NASDAQ: TPTX) today announced the extension of an exclusive collaboration agreement between TorreyPines and Eisai Co., Ltd. that began in February 2005. This collaboration, focusing on the discovery of novel, small molecules to treat Alzheimer’s disease, is TorreyPines’ second discovery collaboration with Eisai. In a separate series of agreements, dating back to 2001, Eisai and TorreyPines are collaborating in a genetics program to discover Alzheimer’s disease targets using whole-genome family-based association screening.
The goal of the small molecule program is to discover novel Alzheimer’s disease modifying compounds based on the study of the mechanism of the disease’s pathogenesis. Under the original agreement, Eisai has exclusive rights of first negotiation and refusal for validated compounds that are discovered through the research. TorreyPines and Eisai may enter into development agreements involving the validated compounds.
“We are excited about extending this agreement with Eisai, a leader in Alzheimer’s disease research and treatment,” said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. “We look forward to advancing the small molecule program further with Eisai’s support, as well as to continuing to work with them on our initial research collaboration to identify genetically-validated pharmaceutical targets for Alzheimer’s disease.”
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics is a clinical stage biopharmaceutical company that discovers and develops small molecule drugs to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver new CNS therapies for chronic pain, including migraine and neuropathic pain; and cognitive disorders, including cognitive impairment associated with schizophrenia and Alzheimer’s disease. TorreyPines’ common stock is traded on The NASDAQ Global Stock Market under the symbol "TPTX." For detailed company information, including copies of this and other press releases, please visit TorreyPines’website at www.torreypinestherapeutics.com...
Source: TorreyPines Therapeutics, Inc [FullText]
Labels: Alzheimer Biotech
posted by Dr.Koudinov @ 24.2.07
0 comments
Latest PubMed 20 review articles on Alzheimer’s
Latest PubMed 20 research articles on Alzheimer’s amyloid
Latest PubMed 50 research titles on Alzheimer’s
